The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...
Discover the latest trends in the business world, from Barnes and Noble's growth fueled by BookTok to the FDA's approval of a new nonopioid pain medication.
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...